BACKGROUND: A growing proportion of head and neck squamous cell carcinoma (HNSCC) is caused by the human papillomavirus (HPV). In light of the unique natural history and prognosis of HPV-related HNSCCs, routine HPV testing is being incorporated into diagnostic protocols. Accordingly, there is an escalating demand for an optimal detection strategy that is sensitive and specific, transferrable to the diagnostic laboratory, standardized across laboratories, cost-effective, and amenable to broad application across specimen types including cytologic preparations. METHODS: Cytologic preparations (fine-needle aspirates [FNAs] and brushes) were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay. HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry. In cases in which the immunohistochemical and in situ hybridization results were discordant, HPV status was determined by real-time polymerase chain reaction detection of E7 expression. HPV status in the tissues and corresponding cytologic samples was compared. RESULTS: Based on benchmark HPV testing of the tissue sections, 14 HNSCCs were classified as HPV positive and 10 as HPV negative. All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay. CONCLUSIONS: The Hybrid Capture 2 strategy, already widely used for the detection of high-risk HPV in cervical brushes, is readily transferrable to HNSCCs. Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases, and may eliminate the need to obtain tissue solely for the purpose of HPV testing.
BACKGROUND: A growing proportion of head and neck squamous cell carcinoma (HNSCC) is caused by the human papillomavirus (HPV). In light of the unique natural history and prognosis of HPV-related HNSCCs, routine HPV testing is being incorporated into diagnostic protocols. Accordingly, there is an escalating demand for an optimal detection strategy that is sensitive and specific, transferrable to the diagnostic laboratory, standardized across laboratories, cost-effective, and amenable to broad application across specimen types including cytologic preparations. METHODS: Cytologic preparations (fine-needle aspirates [FNAs] and brushes) were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay. HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry. In cases in which the immunohistochemical and in situ hybridization results were discordant, HPV status was determined by real-time polymerase chain reaction detection of E7 expression. HPV status in the tissues and corresponding cytologic samples was compared. RESULTS: Based on benchmark HPV testing of the tissue sections, 14 HNSCCs were classified as HPV positive and 10 as HPV negative. All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay. CONCLUSIONS: The Hybrid Capture 2 strategy, already widely used for the detection of high-risk HPV in cervical brushes, is readily transferrable to HNSCCs. Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases, and may eliminate the need to obtain tissue solely for the purpose of HPV testing.
Authors: Francesca Maria Carozzi; Annarosa Del Mistro; Massimo Confortini; Cristina Sani; Donella Puliti; Rossana Trevisan; Laura De Marco; Anna Gillio Tos; Salvatore Girlando; Paolo Dalla Palma; Antonella Pellegrini; Maria Luisa Schiboni; Paola Crucitti; Paola Pierotti; Alberta Vignato; Guglielmo Ronco Journal: Am J Clin Pathol Date: 2005-11 Impact factor: 2.493
Authors: Patrick K Ha; Sara I Pai; William H Westra; Maura L Gillison; Betty C Tong; David Sidransky; Joseph A Califano Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Ming Zhao; Eli Rosenbaum; Andre Lopes Carvalho; Wayne Koch; Weiwen Jiang; David Sidransky; Joseph Califano Journal: Int J Cancer Date: 2005-11-20 Impact factor: 7.396
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: David F Smith; Zahra Maleki; Diarmuid Coughlan; Zhen Gooi; Belinda Akpeng; Takenori Ogawa; Justin A Bishop; Kevin D Frick; Nishant Agrawal; Christine G Gourin; Patrick K Ha; Wayne M Koch; Jeremy D Richmon; William H Westra; Sara I Pai Journal: Oral Oncol Date: 2014-03-12 Impact factor: 5.337
Authors: Jody E Hooper; Jessica F Hebert; Amy Schilling; Neil D Gross; Joshua S Schindler; James P Lagowski; Molly Kulesz-Martin; Christopher L Corless; Terry K Morgan Journal: Appl Immunohistochem Mol Morphol Date: 2015-04
Authors: Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-03-07 Impact factor: 2.503
Authors: M Chernesky; D Jang; J Schweizer; M Arias; L Doerwald-Munoz; M Gupta; B Jackson; S Archibald; J Young; A Lytwyn; M Smieja; A Severini; A Ecobichon-Morris; M Hyrcza Journal: Papillomavirus Res Date: 2018-05-26